Jim Scopa

Jim Scopa is an accomplished professional with extensive experience in the biotechnology and finance sectors. Currently serving as Director and Chair of the Audit Committee at Aligos Therapeutics and Neuron23 Inc., and a Director at Adverum Biotechnologies, where involvement includes the Compensation and Audit Committees. As a member of One Ventures' Investment Advisory Committee and Advisory Board, Jim advises a venture capital firm managing $330 million. Previous roles include Director and Chair of the Compensation Committee at DICE Therapeutics, which was sold to Eli Lilly for $2.4 billion, and Managing Director at MPM Capital, leading investments in successful biotech firms. Jim's financial expertise was honed at Thomas Weisel Partners LLC and Deutsche Bank, specializing in health care investment banking. Educational background includes an MBA and a J.D. from Harvard, along with a degree in History and Science from Harvard University.